SHANGHAI, Oct. 14, 2021 /PRNewswire/ — Qiming Venture Partners’ portfolio company Abbisko (SEHK:2256), a clinical-stage biopharmaceutical company, listed on the main board of the Hong Kong Stock Exchange on October 13. The issue price is HK$ 12.46 per…
Qiming’s Portfolio Company Abbisko Lists on Main Board of HKEx
Share this article
More News



Privacy coins in 2026: Private crypto coins compared
August 5, 2026


Ethereum Based Crypto Presale Pepeto Nears
August 5, 2026

Could Upcoming FY2026 Q4 Earnings Boost Shares to $1,700?
August 5, 2026
